What are the NCCN preferred regimens for treatment of relapsed multiple myeloma (MM)?

Updated: Mar 06, 2020
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

For MM that relapses after more than 6 months, the regimen used for primary induction therapy can be repeated. For relapses that occur sooner,  regimens that are NCCN category 1 preferred include the following [2] :

  • Carfilzomib (twice weekly)/dexamethasone
  • Carfilzomib/lenalidomide/dexamethasone
  • Daratumumab/bortezomib/dexamethasone
  • Daratumumabm/lenalidomide/dexamethasone
  • Elotuzumab/lenalidomide/dexamethasone
  • Ixazomib/lenalidomide/dexamethasone

Isatuximab–pomalidomide–low-dose dexamethasone is approved for relapsed and refractory MM in patients who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor. [6, 7]

See Treatment and Medication for more detail.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!